Vimian Names Lotta Lundaas to Lead MedTech Unit and Join Group Management

The latest update is out from Vimian Group AB ( (SE:VIMIAN) ).

Vimian Group AB has appointed Lotta Lundaas as Head of MedTech and member of the group management team, effective 13 April 2026, strengthening leadership for its veterinary medical technology operations. Lundaas brings over 15 years of senior experience in scaling entrepreneurial companies across technology, telecom and healthcare in Europe and the United States, and will be based in New York.

Chief executive Alireza Tajbakhsh highlighted her track record in driving growth and operational performance as key to accelerating Vimian’s dental and orthopedics medtech businesses. Lundaas said she aims to build Vimian into a global leader in veterinary medtech by leveraging its strong brand portfolio, clinical credibility and niche market positions, while supporting local expertise and deepening collaboration with the veterinary community.

The most recent analyst rating on (SE:VIMIAN) stock is a Sell with a SEK25.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

More about Vimian Group AB

Vimian Group AB is a global animal health company active in Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Headquartered in Stockholm, it serves veterinary clinics and laboratories in more than 80 markets, employing about 1,300 people and generating roughly EUR 425 million in annual revenue by aggregating innovative, entrepreneurial businesses for animal care.

Average Trading Volume: 295,244

Technical Sentiment Signal: Sell

Current Market Cap: SEK13.35B

See more data about VIMIAN stock on TipRanks’ Stock Analysis page.